Sustained improvements across stringent measures of disease in patients with psoriatic arthritis (PsA): One-year improvements were sustained to three years across measures of peripheral arthritis, ...

Patients with psoriatic arthritis (PsA) treated with biologics had lower rates of cardiovascular events and all-cause and cardiovascular mortality but a higher risk for infection-related admissions ...

Please provide your email address to receive an email when new articles are posted on . After three doses of guselkumab, 60% of participants had clinically meaningful improvement in psoriatic ...

Blocking both interleukin-17A/F has been effective for plaque psoriasis and psoriatic arthritis, with one such dual inhibitor, bimekizumab, now approved for these and other conditions. Not all ...

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. There are multiple ongoing trials. Recent ...

Note: The U.S. Food and Drug Administration (FDA) does not approve supplements for safety or effectiveness. Talk to a healthcare professional about whether a supplement is the right fit for your ...

A Prescription Drug User Fee Act target date of March 6, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application ...

Psoriatic arthritis (PsA) can cause toe and foot pain. About 50-70% of people with PsA will have foot abnormalities, and 65% will experience swelling in their toes (dactylitis). Your foot contains 26 ...

While many conditions are invisible, that’s not the case when it involves your skin. Rashes, bumps, lesions or discoloration are not only uncomfortable—they can also make you feel self-conscious.

Active psoriasis was associated with, and potentially a cause of, poorer QoL in patients with PsA, even those with mild disease. PsA made a greater disease impact on women than men in this review, a ...

"In psoriatic arthritis, joint damage can begin early and progress quickly if left untreated, significantly impacting a patient's ability to move, work and maintain independence," said Philip J. Mease ...

Emerging data about benefits of the newer weight-loss drugs for some chronic skin conditions suggests their potential use in dermatology, as well as a role for dermatologists in obesity management.